Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation (n = 39), patients with P53WT refractory solid tumors enrolled to rece...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Gluck, W. Larry, Gounder, Mrinal M., Frank, Richard, Eskens, Ferry, Blay, Jean Yves, Cassier, Philippe A., Soria, Jean-Charles, Chawla, Sant, de Weger, Vincent, Wagner, Andrew J., Siegel, David, De Vos, Filip, Rasmussen, Erik, Henary, Haby A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Phase I Studies
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7211202/
https://ncbi.nlm.nih.gov/pubmed/31359240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00840-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados